Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Alzheimer's disease according to a specific set of internationally recognised diagnostic guidelines (the National Institute on Aging-Alzheimer's Association criteria).
- People whose Alzheimer's disease is at a mild or moderate stage, based on a standard memory and thinking test called the MMSE.
- People whose saliva sample tests positive for a type of bacteria called P. gingivalis (a bacteria associated with gum disease).
- People who have a specific protein called pTau217 in their blood above a certain level, as measured by a blood test.
- People whose caregiver has also given full written agreement to participate alongside them.
- People who are already taking standard Alzheimer's medications (such as donepezil, rivastigmine, galantamine, or memantine), as long as the dose has been unchanged for at least 90 days and no changes are planned during the study.
- People who score 4 or below on a screening tool used to distinguish Alzheimer's disease from other causes of memory problems (confirm with trial site).
Who may not be able to join:
- People who have had cancer requiring treatment affecting the whole body (such as chemotherapy) within the last 5 years.
- People who have had a significant or unstable health condition affecting the heart, lungs, kidneys, liver, stomach or gut, nervous system, or metabolism within the past 6 months.
- People who have had unstable chest pain, significant heart failure, or a heart attack within the past 6 months.
- People whose blood pressure is very high at the screening visit (above 180 systolic or above 100 diastolic).
- People with a history of, or current, major neurological or psychiatric conditions such as schizophrenia, bipolar disorder, or Parkinson's disease.
- People who are currently receiving anti-amyloid treatments or other disease-modifying therapies for dementia.
- People who, in the trial doctor's judgement, have other factors that may prevent safe or full participation in the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephen Dominy, MD, Lighthouse Pharmaceuticals, Inc.
Phone: 858-248-5124
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in ADAS-Cog11
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.